(NASDAQ: NERV) Minerva Neurosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.87%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.28%.
Minerva Neurosciences's earnings in 2026 is -$415,074,589.On average, 5 Wall Street analysts forecast NERV's earnings for 2026 to be -$100,030,617, with the lowest NERV earnings forecast at -$162,995,257, and the highest NERV earnings forecast at -$31,307,612. On average, 5 Wall Street analysts forecast NERV's earnings for 2027 to be -$33,977,145, with the lowest NERV earnings forecast at -$43,374,088, and the highest NERV earnings forecast at -$23,480,709.
In 2028, NERV is forecast to generate -$43,672,256 in earnings, with the lowest earnings forecast at -$67,935,655 and the highest earnings forecast at -$17,121,351.